1. Abbott Laboratories (ABT)
Abbott is one of Wall Street’s top large‑cap healthcare picks thanks to its balanced business and steady execution. The company’s strength in diagnostics, medical devices, and nutrition, three areas that still show solid demand even with a slower economy, is impressive. The company’s margins are likely to rise as it expands its device lineup and benefits from easing supply chain costs.
Turning to Wall Street, Abbott stock has a Strong Buy consensus rating based on 16 Buys and four Holds assigned in the last three months. At $117.75, the average ABT stock price target implies a 33.19% upside potential.
2. Teva Pharmaceutical
Teva is making a major comeback by pushing deeper into branded drugs, biosimilars, and tighter cost control. New migraine and schizophrenia drugs have helped Teva move away from its reliance on generics. Also, steady debt cuts have strengthened its balance sheet. Further, its turnaround is showing momentum with a cleaner legal backdrop and a pipeline that offers clear growth.
